# Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

> **NCT03935893** · PHASE2 · RECRUITING · sponsor: **Udai Kammula** · enrollment: 240 (estimated)

## Conditions studied

- Gastric Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Sarcoma
- Mesothelioma
- Neuroendocrine Tumors
- Squamous Cell Cancer
- Merkel Cell Carcinoma
- Mismatch Repair Deficiency
- Microsatellite Instability

## Interventions

- **BIOLOGICAL:** Tumor Infiltrating Lymphocytes (TIL)
- **DRUG:** Fludarabine + Cyclophosphamide combination

## Key facts

- **NCT ID:** NCT03935893
- **Lead sponsor:** Udai Kammula
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-12-03
- **Primary completion:** 2037-06-30
- **Final completion:** 2038-06-30
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2025-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03935893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03935893, "Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03935893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*